In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
In collaboration with Lundbeck, leadXpro solved the first structure of a human Kv3 channel in complex with a positive modulator.
Together with the Basel Biozentrum and the Institute of Medical Microbiology in Zurich, leadXpro solved the structure of the bacterial transporter LptDE to provide structural basis for the design of novel antibiotics.
In partnership with Bayer, leadXpro has generated protein and solved the cryo-EM structure of human TRPV4 in complex with the agonist 4α-PDD, providing novel information about agonist binding to this important drug target.
In a partnership with Boehringer Ingelheim, leadXpro generated protein and provided the X-ray structure data to advance their drug discovery programs on CCR2, a chemokine receptor target.
Creoptix CEO Line S. Raquet and leadXpro CEO Michael Hennig look back on three years of partnership that transformed membrane protein drug discovery.
leadXpro, PSI, ETH and Sosei Heptares scientists present sensitivity improvements for XFEL measurements by using long wavelength pulses and improvements in data evaluation.
The publication provides evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism for immune evasion by tumors. Inhibition of adenosine signaling through selective small molecule inhibition of A R using AZD4635 restores T cell function
cross-presentation by CD103+ DCs resulting in antitumor immunity.
This crystallography review summarizes the current main strategies in sample delivery and their respective pros and cons, as well as some future direction.
The in meso in situ serial X-ray crystallization method enables structure determination of very fragile crystals.